About Us

Fresenius Kabi at a glance

Our product portfolio comprises a comprehensive range of I.V. generic drugs, infusion therapies and clinical nutrition products as well as the devices for administering these products. In the field of biosimilars, we focus on autoimmune diseases and oncology. In 2019, the first biosimilar product by Fresenius Kabi was launched. Within transfusion medicine and cell therapies, Fresenius Kabi offers products for collection of blood components and extracorporeal therapies.

About us

Fresenius Kabi employs more than 42,000 people worldwide.

With our corporate philosophy of "caring for life", we are committed​ to putting essential medicines and technologies in the hands of people who help patients and finding the best answers to the challenges they face.

Following our “Vision 2026”, we are furthermore committed to increase efficiencies in the therapy and care of patients and improve access to high-quality healthcare around the globe. We aspire to be leading globally in our product segments – all for the benefit of patients, our customers, and our stakeholders.

In 2022, the company reported sales of more than €7.8 billion. Fresenius Kabi AG is a wholly owned subsidiary of the Fresenius SE & Co. KGaA healthcare group.

Key Figures

€ in millions 2022 2021
Sales 7,850 7,193
EBITDA1 1,576 1,601
EBIT1 1,080 1,153
Net Income1,2 780 778
Employees (Dec 31) 42,063 41,397

1 On a comparable basis: before special items and adjusted for IFRS 16 effect
Net income attributable to shareholders of Fresenius SE & Co. KGaA